BioNexus Gene Lab Corp. Short Interest Up 670.5 percent in September
BGLC Stock | USD 0.25 0.04 13.79% |
About 61% of BioNexus Gene's investor base is looking to short. The analysis of overall sentiment of trading BioNexus Gene Lab stock suggests that many investors are alarmed at this time. The current market sentiment, together with BioNexus Gene's historical and current headlines, can help investors time the market. In addition, many technical investors use BioNexus Gene Lab stock news signals to limit their universe of possible portfolio assets.
BioNexus |
BioNexus Gene Lab Corp. saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 852,200 shares, an increase of 670.5 percent from the August 31st total of 110,600 shares. Based on an average daily volume of 369,600 shares, the short-interest
Read at thelincolnianonline.com
BioNexus Gene Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BioNexus Gene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioNexus Gene Fundamental Analysis
We analyze BioNexus Gene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNexus Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNexus Gene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
BioNexus Gene is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
BioNexus Gene Lab Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioNexus Gene stock to make a market-neutral strategy. Peer analysis of BioNexus Gene could also be used in its relative valuation, which is a method of valuing BioNexus Gene by comparing valuation metrics with similar companies.
Peers
BioNexus Gene Related Equities
GEVO | Gevo | 8.18 | ||||
SNES | SenesTech | 4.39 | ||||
OEC | Orion Engineered | 4.04 | ||||
FUL | H B | 2.40 | ||||
LOOP | Loop Industries | 2.13 | ||||
CMT | Core Molding | 1.54 | ||||
GLGI | Greystone Logistics | 1.02 | ||||
NEU | NewMarket | 0.32 | ||||
IOSP | Innospec | 0.17 | ||||
BCPC | Balchem | 0.14 | ||||
AVOA | Avoca LLC | 0.00 | ||||
PRM | Perimeter Solutions | 0.15 | ||||
GVDNY | Givaudan | 0.49 | ||||
ALTO | Alto Ingredients | 1.41 | ||||
NNOMF | Nano One | 1.72 | ||||
GEVI | General Environmental | 5.56 | ||||
CRKN | Crown Electrokinetics | 36.36 |
Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies |